Kymera Therapeutics Inc
KYMR
NASDAQ
Biotechnology
$117.39
USD
+2.97 (+2.60%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $9.48B
Volume 468.5K
Revenue
$105.00M
TTM
+134.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-299.60M
TTM
-8.8%
YoY
Operating Cash Flow
$-236.76M
TTM
+5.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 11.5 | 2.8 | 2.9 | 34.4 | 65.0 |
YoY Growth | -55.3% | -26.1% | -61.2% | +55.5% | +466.4% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 11.5 | 2.8 | 2.9 | 34.4 | 65.0 |
Selling, General & Administrative | 17.6 | 17.3 | 16.9 | 20.4 | 21.1 |
Other Operating Expenses | 0.0 | 3.9 | 0.0 | 0.1 | 0.0 |
Total Operating Expenses | 96.0 | 95.3 | 100.8 | 118.6 | 140.6 |
Operating Income | -84.6 | -92.5 | -97.9 | -84.2 | -75.6 |
EBITDA | -82.5 | -86.5 | -95.9 | -82.2 | -73.6 |
Other Income / Expense | -0.1 | 0.0 | 38.0 | 15.0 | -0.1 |
Total Other Income / Expense | 7.9 | 10.3 | 10.9 | 15.0 | 14.4 |
Income Before Income Taxes | -76.6 | -82.2 | -87.0 | -69.2 | -61.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -76.6 | -82.2 | -87.0 | -69.2 | -61.2 |
Consolidated Net Income / Loss | -76.6 | -82.2 | -87.0 | -69.2 | -61.2 |
Net Income Attributable to Common Shareholders | -76.6 | -82.2 | -87.0 | -69.2 | -61.2 |
Basic EPS | -$0.95 | -$0.94 | -$0.97 | -$0.71 | -$0.62 |
Diluted EPS | -$0.95 | -$0.94 | -$0.97 | -$0.71 | -$0.62 |
Basic Shares Outstanding | 80.4M | 87.3M | 90.1M | 97.5M | 98.2M |
Diluted Shares Outstanding | 80.4M | 87.3M | 90.1M | 97.5M | 98.2M |